| Entry |
|
|---|
| Name |
Bivalirudin (USAN/INN);
Angiomax (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C98H138N24O33
|
|---|
| Exact mass |
2178.9858
|
|---|
| Mol weight |
2180.2853
|
|---|
| Sequence |
FPRPGGGGNG DFEEIPEEYL |
|---|
| Type |
Peptide |
|---|
| Class |
|
|---|
| Remark |
|
|---|
| Efficacy |
Anticoagulant, Thrombin inhibitor |
|---|
| Comment |
Peptide
Hirudin derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04610 | Complement and coagulation cascades |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AE Direct thrombin inhibitors
B01AE06 Bivalirudin
D03136 Bivalirudin (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Immune system
Complement and coagulation
F2
D03136 Bivalirudin (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D03136
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03136
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03136
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
